NeuroSense Therapeutics L... (NRSN)
0.91
-0.02 (-2.14%)
At close: Apr 01, 2025, 2:55 PM
-2.14% (1D)
| Bid | 0.9 |
| Market Cap | 21.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.74M |
| EPS (ttm) | -0.76 |
| PE Ratio (ttm) | -1.2 |
| Forward PE | -1.89 |
| Analyst | n/a |
| Ask | 0.91 |
| Volume | 139,083 |
| Avg. Volume (20D) | 154,211 |
| Open | 0.92 |
| Previous Close | 0.93 |
| Day's Range | 0.88 - 0.98 |
| 52-Week Range | 0.51 - 2.25 |
| Beta | 1.26 |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 9, 2021
Employees 18
Stock Exchange NASDAQ
Ticker Symbol NRSN
Website https://www.neurosense-tx.com
3 months ago
+12.28%
NeuroSense Therapeutics shares are trading higher....
Unlock content with
Pro Subscription
4 months ago
+14.27%
NeuroSense Therapeutics shares are trading higher after the company announced its CEO purchased $5 million worth of ordinary shares in a private placement.
